Chemomab Therapeutics Reports Data From Secondary Analysis Of Phase 2a Liver Fibrosis Trial In NASH Patients Showing Treatment With Cm-101 Improves Additional Biomarkers Of Fibrosis And Inflammation, Reinforcing And Extending Initial Study Results
Portfolio Pulse from Benzinga Newsdesk
Chemomab Therapeutics reports positive data from a secondary analysis of its Phase 2a liver fibrosis trial in NASH patients, showing that treatment with CM-101 improves additional biomarkers of fibrosis and inflammation, reinforcing and extending initial study results.
June 21, 2023 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chemomab Therapeutics' Phase 2a liver fibrosis trial in NASH patients shows positive results, with CM-101 improving additional biomarkers of fibrosis and inflammation.
The positive results from the secondary analysis of Chemomab Therapeutics' Phase 2a liver fibrosis trial in NASH patients indicate that CM-101 improves additional biomarkers of fibrosis and inflammation. This reinforces and extends the initial study results, which could lead to increased investor confidence and a potential short-term increase in the stock price of CMMB.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100